Earnings live updates: Citi and BlackRock stocks rise on strong results, Johnson & Johnson profit beats estimates

Q1 earnings season is starting with Wall Street expecting the S&P 500 to post its sixth straight quarter of double-digit earnings growth, with analysts now forecasting 13.2% year-over-year EPS growth. Early reports were mostly positive: Citigroup posted 42% profit growth to $5.8 billion and EPS of $3.06 versus $2.63 expected, BlackRock beat on both EPS ($12.53 vs. $11.50) and revenue ($6.7 billion vs. $6.4 billion), and Johnson & Johnson topped estimates with EPS of $2.70 and revenue of $24 billion while lifting full-year EPS guidance to $11.45-$11.65. Wells Fargo beat EPS estimates but missed on revenue and net interest income, while Fastenal was in line but fell on a flat growth outlook.

Analysis

The key market signal is not the headline earnings beats, but the widening dispersion beneath them: financials are still the cleanest way to express a late-cycle “higher-for-longer” environment, while rate-sensitive and margin-fragile names are already showing cracks. Citi and JPM are benefiting from active capital markets and trading activity, which tends to be a short-duration tailwind; if that strength persists for another 1-2 quarters, it can justify multiple expansion versus the broader bank group. By contrast, Wells Fargo’s miss-plus-guidance pattern suggests deposit and funding pressure remains an issue even when credit is stable, making it the weak link if the curve stays flat.

BlackRock is the most interesting second-order winner because a strong risk-asset tape feeds directly into fee growth, and its operating leverage is asymmetric when markets are calm. If AUM momentum continues, it can outperform not just asset managers but also insurers and custodians that are more exposed to balance-sheet income than market-linked fees. The contrarian risk is that this is a sentiment-sensitive trade: one sharp drawdown in equities or a volatility spike can compress flows and quickly unwind the “best-in-class” premium.

JNJ looks like a transitional story where the market is likely underappreciating how much the mix shift matters. The offset to patent erosion matters more than the absolute beat: if newer growth assets keep comping above the mature portfolio runoff, the multiple can stabilize even with only mid-single-digit EPS growth. ASML and NFLX are more timing-sensitive than fundamental story-sensitive here; both may remain rangebound until next catalyst visibility improves, so chasing them before prints is lower-quality risk than expressing views through pairs. For Fastenal, the negative read-through is broader than one industrial distributor: margin pressure at a bellwether tends to precede cautious commentary across cyclical midcaps by 1-2 quarters.

Key Decisions for Investors

• Long C / short WFC for 1-2 quarters: express stronger trading/fee momentum versus a bank still facing funding and NII pressure; target relative outperformance if rates stay elevated and capital markets remain active.
• Add BLK on pullbacks over the next 1-3 weeks: best leveraged beneficiary to stable-to-rising risk assets; pair against a lower-beta asset manager or financials basket to isolate AUM/flow operating leverage.
• Initiate a JNJ call spread into the print/guidance window: upside is limited but defensible if oncology/psoriasis growth continues to offset Stelara erosion; use as a low-volatility compounder rather than a momentum trade.
• Short FAST or hedge industrial cyclicals for 1-2 quarters: weak margin tone at a bellwether often leads broader sell-side estimate cuts across the distribution/industrial supply chain.
• Avoid initiating fresh long ASML/NFLX ahead of catalysts; prefer buying post-event if guidance is conservative and implied volatility resets, since both names appear more timing-driven than fundamentally mispriced today.